LAIYANG, China, July 23 /Xinhua-EMWNews/ -- Genesis

Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or

the "Company"), a leading pharmaceutical company in the People's Republic

of China, held a Board of Directors meeting on July 18, 2008 at which a new

Board member was appointed to serve on the Board of Directors of the

Company, and an Audit Committee and a Compensation Committee were formed.



    Mr. Michael Marks was appointed to the Company's Board of Directors on

July 18, 2008. Since 2007, he has served as an independent director of

China Housing & Land Development, Inc., a property developer in China. In

2006, Mr. Marks became President of Middle Kingdom Alliance Corp., a

publicly traded Special Purpose Acquisition Corporation active in China. In

2003, Mr. Marks founded the China practice of Sonnenblick Goldman, a real

estate investment bank, and served as its Managing Director in China until

2007. In 2001, he founded B2Globe, providing technology solutions to

international internet businesses in Asia. In 1999, he co-founded Metro

Corporate Training in Shanghai to offer training and management

development, and was its Chief Executive Officer until 2001. During his

nine-year tenure in China, Mr. Marks has had a role as advisor, banker or

principal in over $2 billion of transactions. From 1998 to 1999, Mr. Marks

worked as a management consultant with Horwath Asia Pacific in Australia

and China. From 1995 to 1998, Mr. Marks worked in the audit, corporate

finance and advisory divisions of PricewaterhouseCoopers in South Africa.

Mr. Marks received a Bachelor of Commerce (Honors) in 1994 and Masters of

Commerce in 1997 from the University of the Witwatersrand in Johannesburg,

South Africa. In 1998, he graduated with a Bachelor of Arts (Psychology)

degree from the University of South Africa. In 1997, Mr. Marks became a

Chartered Accountant in South Africa, and a Fellow of the Association of

International Accountants in the United Kingdom in 1999. He speaks fluent

Mandarin, French and English.



    The Board of Directors accepted the resignations of Mr. Zhang Yihua and

Mr. Rodrigo Arboleda. The resignations of Mr. Zhang and Mr. Arboleda from

the Company's Board of Directors were not the result of any disagreements

with the Company on any matter relating to the Company's operations,

policies or practices.



    "I look forward to working with Genesis," stated Michael Marks. "Having

participated in the growth of a number of companies in China, I know that

Genesis is a company with a tremendous future. I am excited to be a part of

its development."



    The Board of Directors authorized and approved creation of an Audit

Committee that will oversee matters relating to the Company's financial

reporting. Qualifying as an "audit committee financial expert" in

compliance with applicable SEC and current stock exchange rules and

regulations, Michael Marks was appointed as the Chairman of the Audit

Committee. Each member of the Audit Committee is "independent" as defined

in Section 10A of the Securities Exchange Act of 1934.



    The Board of Directors also authorized and approved creation of a

Compensation Committee that will, among other things, make recommendations

to the Board of Directors concerning salaries and incentive compensation

for the Company's officers. Feng Xiaowei was appointed as the Chairman of

the Compensation Committee. Each member of the Compensation Committee is

"independent" as defined in Section 10A of the Securities Exchange Act of

1934.



    "We are pleased to welcome Michael Marks to serve as a member of our

Board of Directors. We believe that he will make an immediate and valuable

contribution to the work of our Board," said Mr. Cao Wubo, Chairman and CEO

of Genesis Pharmaceuticals Enterprises. "At its last meeting, our Board of

Directors created an Audit Committee and Compensation Committee composed of

independent Board members. We believe that the establishment of these

committees will help to assure investors that Genesis is fully committed to

the highest possible standards of corporate governance."

    About Genesis Pharmaceuticals Enterprises, Inc.



    Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company

engaged in the research, development, production, marketing and sales of

pharmaceutical products in the People's Republic of China. Its operations

are located in Northeast China in an Economic Development Zone in Laiyang

City, Shandong province. Genesis is a major pharmaceutical company in China

producing tablets, capsules, and granules for both western and Chinese

herbal- based medical drugs.



    Safe Harbor Statement



    Certain statements in this press release that are not historical facts

are "forward-looking statements" within the meaning of the Private

Securities Litigation Reform Act of 1995. Such statements are not

guarantees of future performance and are subject to risks and uncertainties

that could cause the Company's actual results and financial position to

differ materially from those included within the forward-looking

statements. Forward-looking statements involve risks and uncertainties,

including those relating to the Company's ability to introduce, manufacture

and distribute new drugs. Actual results may differ materially from

anticipated or predicted results, and reported results should not be

considered as an indication of future performance. The potential risks and

uncertainties include, among others, the Company's ability to obtain raw

materials needed in manufacturing, the continuing employment of key

employees, the failure risks inherent in testing any new drug, the

possibility that regulatory approvals may be delayed or become unavailable,

patent or licensing concerns that may include litigation, direct

competition from other manufacturers and product obsolescence. More

information about the potential factors that could affect the Company's

business and financial results is included in the Company's filings,

available via the United States Securities and Exchange Commission.






    For more information, please contact:



    Genesis Pharmaceuticals Enterprises, Inc.

     Ms. Elsa Sung, CFO

     Tel:   +1-954-727-8436

     Email: [email protected]

     Web:   http://www.genesis-china.net



    CCG Investor Relations, Inc.

     Mr. Crocker Coulson, President

     Tel:   +1-646-213-1915

     Email: [email protected]

     Web:   http://www.ccgir.com